OncoZenge AB (8LY) Price & Analysis

0 Followers

8LY Stock Chart & Stats

€0.59

-€0.02(-7.82%)

At close: Jan 08 4:00 PM EST

€0.59

-€0.02(-7.82%)

Day’s Range― - ―

52-Week Range€0.45 - €0.75

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€8.02M

Enterprise Value€108.32

Total Cash (Recent Filing)€749.00K

Total Debt (Recent Filing)€7.50M

Price to Earnings (P/E)―

Beta0.28

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.92

Shares Outstanding14,820,865

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.07

Price to Book (P/B)-139.70

Price to Sales (P/S)30.78

P/FCF Ratio-6.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.09

Revenue Forecast (FY)€924.04K

Bulls Say, Bears Say

Bulls Say

Revenue GrowthRevenue more than doubled from a low base, indicating improving commercialization traction for the company’s product. Sustained growth could gradually improve operating leverage if adoption expands faster than the cost base.

Positive Gross ProfitPositive gross profit suggests the product can generate economic value before operating expenses. If sales scale, this provides a foundation for improving margins, although substantial investment is still required to reach overall profitability.

Focused Supportive-Care ProductThe company targets a defined supportive-care need within oncology rather than pursuing a broad pipeline. A focused product strategy may concentrate development resources and support partnering or commercialization opportunities if clinical and regulatory requirements are met.

Bears Say

Persistent Operating LossesLosses remain very large relative to revenue, showing that the current cost base is not yet supported by operations. Continued deficits could delay self-sustaining profitability and require further financing or spending reductions.

Heavy Cash BurnSubstantial cash consumption indicates that operations and development remain dependent on external capital. Even with some free-cash-flow improvement, ongoing burn can constrain investment capacity and increase dilution or refinancing risk.

Weak Balance SheetNegative equity and meaningful debt indicate limited financial flexibility and elevated solvency risk. The balance-sheet position may restrict funding options, increase dependence on investors or partners, and make execution more vulnerable to delays.

OncoZenge AB News

OncoZenge’s BupiZenge Heads Into Phase III: What This Pain Study Means for Investors

OncoZenge AB ($DE:8LY) announced an update on their ongoing clinical study. The phase III trial “A Randomized, Open-label,...

2M ago

8LY

8LY FAQ

What was OncoZenge AB’s price range in the past 12 months?

OncoZenge AB lowest stock price was €0.45 and its highest was €0.75 in the past 12 months.

What is OncoZenge AB’s market cap?

OncoZenge AB’s market cap is €8.02M.

When is OncoZenge AB’s upcoming earnings report date?

OncoZenge AB’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.

How were OncoZenge AB’s earnings last quarter?

OncoZenge AB released its earnings results on Aug 27, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is OncoZenge AB overvalued?

According to Wall Street analysts OncoZenge AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoZenge AB pay dividends?

OncoZenge AB does not currently pay dividends.

What is OncoZenge AB’s EPS estimate?

OncoZenge AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoZenge AB have?

OncoZenge AB has 14,820,865 shares outstanding.

What happened to OncoZenge AB’s price movement after its last earnings report?

OncoZenge AB reported an EPS of -€0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.21%.

Which hedge fund is a major shareholder of OncoZenge AB?

Currently, no hedge funds are holding shares in DE:8LY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoZenge AB

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).